Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.67 |
| ▸ | PGK1 | P00558 | 1/20 | 0.64 |
| ▸ | PGK2 | P07205 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nelarabine SCHEMBL31326718 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL9937290 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL14031852 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18820 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13575801 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL2143756 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18321891 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13657986 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL20769831 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL29077509 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724107-A2 | OPHTHALMIC FILMS | Fount Bio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254278-A9 | OPHTHALMIC FILMS | FOUNT BIO, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024254278-A2 | OPHTHALMIC FILMS | FOUNT BIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-113710225-B | Delivery and retention of active agents within the skin | 范德生物公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-108350030-B | Skin permeable peptides and methods of use thereof | 汉阳大学校产学协力团 | 2022-12-13 | — | — | CN | disclosed |
| US-20220175819-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | FOUNT BIO, INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3955887-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | Fount Bio, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113710225-A | Delivery and retention of active agents within the skin | 范德生物公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3336098-B1 | SKIN PERMEABLE PEPTIDE AND METHOD FOR USING SAME | IUCF HYU (KR) | 2021-08-11 | — | — | EP | disclosed |
| US-10858395-B2 | Skin-penetrating peptide and method for using same | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2020-12-08 | — | — | US | disclosed |
| US-8518871-B2 | Skin permeating and cell entering (SPACE) peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-27 | — | — | US | disclosed |
| CN-103201386-A | Skin penetrating and cell entering (SPACE) peptides and methods of use thereof | UNIV CALIFORNIA | 2013-07-10 | — | — | CN | disclosed |
| US-20130011392-A1 | METHOD FOR ASSESSING THE ABILITY OF A PATIENT TO RESPOND TO OR BE SAFELY TREATED BY A NUCLEOSIDE ANALOG BASED-CHEMOTHERAPY | ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE (FR) | 2013-01-10 | — | — | US | disclosed |
| WO-2012064429-A2 | SKIN PERMEATING AND CELL ENTERING (SPACE) PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011061278-A1 | A METHOD FOR ASSESSING THE ABILITY OF A PATIENT TO RESPOND TO OR BE SAFELY TREATED BY A NUCLEOSIDE ANALOG BASED-CHEMOTHERAPY | UNIVERSITE DE LA MEDITERRANEE (FR) | 2011-05-26 | — | — | WO | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-0539479-A1 | HETEROCYCLIC COMPOUNDS. | WELLCOME FOUND (GB) | 1993-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175819-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | MMP8, MMP7, MMP1 | CYP2C19 4669/4885ADORA2A 1212/4885ADORA3 1854/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | CYP2C19 889/4885ADORA2A 573/4885ADORA3 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.